Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer

pharmaceutical-business-reviewNovember 24, 2020

Tag: Zymeworks , Zanidatamab , EC , gastric cancer

PharmaSources Customer Service